[Clinical pathway in Chinese county for lung cancer diagnosis and treatment (2023 edition)].

Y L Wu, Q Zhou
{"title":"[Clinical pathway in Chinese county for lung cancer diagnosis and treatment (2023 edition)].","authors":"Y L Wu, Q Zhou","doi":"10.3760/cma.j.cn112152-20230928-00162","DOIUrl":null,"url":null,"abstract":"<p><p>Lung cancer (LC) is the leading cause of death among patients with cancer both in worldwide and China. China accounts for 11.4% of the total number of cancer cases and 18.0% of the total number of cancer deaths in the world. Standardizing the diagnosis and treatment of LC is a key measure to improve the survival rate of LC patients and reduce the mortality rate. However, county hospitals generally face the problem of inaccessibility to advanced diagnostic and treatment technologies. Therefore, when developing quality control standards and clinical diagnosis and treatment specifications, it is necessary to combine the actual situation of county hospitals and formulate specific recommendations. The recommendations of treatment measures also need to consider the approval status of indications and whether it is included in the National Reimbursement Drug List (NRDL), to ensure the access to medicines. In order to solve the above problems, based on existing guidelines at home and abroad and the clinical work characteristics of county hospitals, the first clinical pathway in Chinese county for LC diagnosis and treatment (2023 edition) was compiled. This pathway elaborated on the imaging diagnosis, pathological diagnosis, molecular testing, and precision medicine based on histological-pathological types, tumor-node-metastasis (TNM) classification, and molecular classification, developed different diagnosis and treatment processes for different types of LC patients. Simultaneously, according to the actual work situation of county hospitals, the diagnosis and treatment recommendations in clinical scenarios are divided into basic strategies and optional strategies for elaboration. The basic strategies are the standards that county hospitals must meet, while the optional strategies provide more choices for hospitals, which are convenient for county doctors to put into clinical practice. All the recommended diagnostic and treatment plans strictly refer to existing guidelines and consensus, ensuring the scientificity.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华肿瘤杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112152-20230928-00162","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Lung cancer (LC) is the leading cause of death among patients with cancer both in worldwide and China. China accounts for 11.4% of the total number of cancer cases and 18.0% of the total number of cancer deaths in the world. Standardizing the diagnosis and treatment of LC is a key measure to improve the survival rate of LC patients and reduce the mortality rate. However, county hospitals generally face the problem of inaccessibility to advanced diagnostic and treatment technologies. Therefore, when developing quality control standards and clinical diagnosis and treatment specifications, it is necessary to combine the actual situation of county hospitals and formulate specific recommendations. The recommendations of treatment measures also need to consider the approval status of indications and whether it is included in the National Reimbursement Drug List (NRDL), to ensure the access to medicines. In order to solve the above problems, based on existing guidelines at home and abroad and the clinical work characteristics of county hospitals, the first clinical pathway in Chinese county for LC diagnosis and treatment (2023 edition) was compiled. This pathway elaborated on the imaging diagnosis, pathological diagnosis, molecular testing, and precision medicine based on histological-pathological types, tumor-node-metastasis (TNM) classification, and molecular classification, developed different diagnosis and treatment processes for different types of LC patients. Simultaneously, according to the actual work situation of county hospitals, the diagnosis and treatment recommendations in clinical scenarios are divided into basic strategies and optional strategies for elaboration. The basic strategies are the standards that county hospitals must meet, while the optional strategies provide more choices for hospitals, which are convenient for county doctors to put into clinical practice. All the recommended diagnostic and treatment plans strictly refer to existing guidelines and consensus, ensuring the scientificity.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[中国县域肺癌诊治临床路径(2023 年版)"。
肺癌(LC)是全球和中国癌症患者的首要死因。中国肺癌发病人数占世界癌症发病总人数的 11.4%,死亡人数占世界癌症死亡总人数的 18.0%。规范 LC 的诊断和治疗是提高 LC 患者生存率、降低死亡率的关键措施。然而,县级医院普遍面临无法获得先进诊疗技术的问题。因此,在制定质量控制标准和临床诊疗规范时,要结合县级医院的实际情况,制定具体的建议。在诊疗措施建议中,还需要考虑适应症的审批情况,是否纳入国家报销药品目录(NRDL),确保药品的可及性。为解决上述问题,在国内外现有指南的基础上,结合县级医院临床工作特点,编制了我国首个县域 LC 诊疗临床路径(2023 年版)。该路径以组织病理分型、肿瘤-结节-转移(TNM)分型、分子分型为基础,从影像诊断、病理诊断、分子检测、精准医疗等方面进行阐述,针对不同类型的LC患者制定了不同的诊疗流程。同时,根据县级医院的实际工作情况,将临床情景下的诊疗建议分为基本策略和可选策略进行阐述。基本策略是县级医院必须达到的标准,而可选策略则为医院提供了更多的选择,便于县级医院医生在临床实践中运用。所有推荐的诊疗方案均严格参考现有指南和共识,确保科学性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
中华肿瘤杂志
中华肿瘤杂志 Medicine-Medicine (all)
CiteScore
1.40
自引率
0.00%
发文量
10433
期刊介绍:
期刊最新文献
[International comparison and assessment of the quality of drug clinical trial implementation in China based on scientific regulatory system]. [A case of primary giant gastrointestinal stromal tumor of the liver]. [Chinese multidisciplinary expert consensus on the rational use of surufatinib in clinical practice(2024 edition)]. [Clinical predictive value of PD-1/PD-L1-induced electrocardiogram changes for cardiotoxicity]. [CT measurement of blood perfusion in hepatocellular carcinoma: from basic principle, measurement methods to clinical application].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1